Fulcrum's Losses Mount to $54.5M Amidst Zero Collaboration Revenue

TL;DR

**FULC is burning cash with no collaboration revenue, making its future funding highly uncertain and a major red flag for investors.**

AI Summary

Fulcrum Therapeutics, Inc. reported a significant net loss of $54.5 million for the nine months ended September 30, 2025, a substantial increase from a net income of $6.8 million in the same period of 2024. This shift is primarily due to the absence of collaboration revenue, which was $80.0 million in the nine months ended September 30, 2024, and zero in 2025. Operating expenses decreased, with research and development falling to $40.7 million from $51.7 million, and general and administrative expenses decreasing to $21.4 million from $28.7 million year-over-year. The company's cash and cash equivalents declined to $47.1 million as of September 30, 2025, from $58.2 million at December 31, 2024, and marketable securities also decreased to $153.6 million from $182.8 million. Fulcrum's accumulated deficit grew to $573.9 million by September 30, 2025, up from $519.4 million at December 31, 2024, indicating continued unprofitability. The company explicitly states it will need substantial additional funding to support its ongoing clinical trial of pociredir and other product development programs.

Why It Matters

Fulcrum's escalating net loss of $54.5 million and the complete absence of collaboration revenue in 2025, compared to $80.0 million in 2024, signals a critical funding challenge for investors. This financial deterioration directly impacts the company's ability to advance its sole clinical-stage product candidate, pociredir, and other pipeline assets, potentially delaying or halting development. For employees, this raises concerns about job security and the long-term viability of the company's research efforts. Customers awaiting new treatments for rare diseases face increased uncertainty regarding the availability of Fulcrum's potential therapies, especially given the competitive landscape where other biotechs are also vying for market share in genetically-defined rare diseases.

Risk Assessment

Risk Level: high — The company explicitly states it has incurred significant losses, with a net loss of $54.5 million for the nine months ended September 30, 2025, and an accumulated deficit of $573.9 million. Furthermore, it warns, "We will need substantial additional funding. If we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate our product development programs or commercialization efforts." This direct admission of needing substantial additional funding, coupled with a declining cash position from $58.2 million to $47.1 million, indicates a high financial risk.

Analyst Insight

Investors should exercise extreme caution and consider reducing exposure to FULC given the significant net losses and the explicit need for substantial additional funding. Monitor closely for any announcements regarding new collaboration agreements or successful capital raises, as these would be critical for the company's survival and continued development of pociredir.

Financial Highlights

debt To Equity

N/A

revenue

$0

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

-$54.5M

eps

N/A

gross Margin

N/A

cash Position

$47.1M

revenue Growth

-100.0%

Revenue Breakdown

Key Numbers

• $54.5M — Net Loss (Increased from a $6.8M net income in the prior year period, primarily due to zero collaboration revenue.)
• $0 — Collaboration Revenue (Down from $80.0M in the nine months ended September 30, 2024, indicating a significant loss of income.)
• $573.9M — Accumulated Deficit (Increased from $519.4M at December 31, 2024, highlighting sustained unprofitability.)
• $47.1M — Cash and Cash Equivalents (Decreased from $58.2M at December 31, 2024, reducing the company's liquidity.)
• $153.6M — Marketable Securities (Decreased from $182.8M at December 31, 2024, further impacting available capital.)
• $40.7M — Research and Development Expenses (Decreased from $51.7M in the prior year, potentially reflecting cost-cutting or reduced program activity.)
• 54,118,438 — Common Shares Outstanding (As of October 22, 2025, indicating potential for dilution if more capital is raised via equity.)

Key Players & Entities

• Fulcrum Therapeutics, Inc. (company) — registrant
• pociredir (product) — sole clinical-stage product candidate
• CAMP4 Therapeutics Corp. (company) — exclusive global license agreement partner
• U.S. Food and Drug Administration (regulator) — regulatory authority for product approvals
• Nasdaq Global Market (market) — exchange where common stock is registered
• $54.5 million (dollar_amount) — net loss for nine months ended September 30, 2025
• $80.0 million (dollar_amount) — collaboration revenue for nine months ended September 30, 2024
• $573.9 million (dollar_amount) — accumulated deficit as of September 30, 2025
• $47.1 million (dollar_amount) — cash and cash equivalents as of September 30, 2025
• $153.6 million (dollar_amount) — marketable securities as of September 30, 2025

FAQ

Risk Factors

• Need for Substantial Additional Financing [high — financial]: The company explicitly states it will need substantial additional funding to support its ongoing clinical trial of pociredir and other product development programs. This is a critical dependency for continued operations and program advancement.
• Clinical Trial and Development Risks [high — operational]: Product candidates require significant additional research, preclinical and clinical testing, and regulatory approval. There is uncertainty regarding the timing and success of these efforts, and whether significant revenue will ever be realized.
• Regulatory Approval Uncertainty [high — regulatory]: The company relies on obtaining regulatory approval for its product candidates. Failure to secure approval will prevent commercialization and revenue generation.
• Sustained Unprofitability and Accumulated Deficit [high — financial]: The company has incurred recurring losses, with an accumulated deficit of $573.9 million as of September 30, 2025, up from $519.4 million at December 31, 2024. This highlights a history of unprofitability.
• Declining Cash and Marketable Securities [medium — financial]: Cash and cash equivalents decreased to $47.1 million from $58.2 million, and marketable securities decreased to $153.6 million from $182.8 million. This reduction in liquid assets impacts operational flexibility.
• Dependence on Key Personnel [medium — operational]: As a biotechnology company, Fulcrum is subject to risks associated with dependence on key personnel for its research and development efforts.
• Reliance on Third-Party Organizations [medium — operational]: The company relies on third-party organizations for various aspects of its product development, introducing potential operational risks and dependencies.
• Competitive Landscape and Innovation [medium — market]: The company faces risks from competitors developing technological innovations, which could impact its market position and the viability of its product candidates.

Industry Context

Fulcrum Therapeutics operates in the highly competitive biotechnology sector, focusing on developing small molecules for rare diseases. The industry is characterized by long development cycles, significant capital requirements, and high failure rates in clinical trials. Success hinges on innovation, effective clinical execution, and securing substantial funding for research and development.

Regulatory Implications

As a biotechnology company, Fulcrum is subject to stringent regulatory oversight from bodies like the FDA. The success of its product candidates, such as pociredir, is contingent upon navigating complex and lengthy approval processes. Failure to meet regulatory standards or obtain approval poses a significant risk to the company's future.

What Investors Should Do

1. Monitor cash burn rate and future financing activities.
2. Evaluate progress and news related to pociredir clinical trials.
3. Assess the impact of the loss of collaboration revenue.
4. Consider the risk of equity dilution.

Key Dates

• 2025-09-30: Nine months ended September 30, 2025 — Reported a net loss of $54.5 million, a significant shift from net income in the prior year, driven by the absence of collaboration revenue.
• 2024-09-30: Nine months ended September 30, 2024 — Reported $80.0 million in collaboration revenue, contributing to net income in that period.
• 2025-09-30: Consolidated Balance Sheet Date — Company held $47.1 million in cash and cash equivalents and $153.6 million in marketable securities.
• 2024-12-31: Balance Sheet Date — Company held $58.2 million in cash and cash equivalents and $182.8 million in marketable securities.
• 2025-09-30: Accumulated Deficit — Grew to $573.9 million, indicating continued unprofitability.
• 2024-02-25: Form 10-K Filing — Previous year's audited financial statements and notes were made available for comparison.

Glossary

Accumulated Deficit

The total cumulative net losses of a company since its inception, minus any cumulative net income. (Indicates the company's long-term unprofitability, which has grown to $573.9 million.)

Collaboration Revenue

Revenue generated from partnerships or collaborations with other companies, often involving shared development or commercialization of products. (The absence of $80.0 million in collaboration revenue in the current period is the primary driver of the net loss.)

Pociredir

A specific product candidate being developed by Fulcrum Therapeutics. (The ongoing clinical trial for pociredir requires substantial additional funding.)

Net Loss

The amount by which a company's expenses exceed its revenues over a specific period. (Fulcrum reported a significant net loss of $54.5 million for the nine months ended September 30, 2025.)

Marketable Securities

Investments in financial instruments that are readily convertible to cash, such as stocks and bonds. (A decrease in marketable securities from $182.8 million to $153.6 million impacts the company's available capital.)

Research and Development Expenses

Costs incurred by a company in the process of developing new products or improving existing ones. (These expenses decreased to $40.7 million from $51.7 million, potentially reflecting cost management or program shifts.)

General and Administrative Expenses

Costs associated with the overall management and operation of a business, not directly tied to production or sales. (These expenses decreased to $21.4 million from $28.7 million, indicating cost control measures.)

GAAP

Generally Accepted Accounting Principles, the common set of accounting principles, standards, and procedures that companies must follow when they compile their financial statements. (The financial statements are prepared in conformity with GAAP.)

Year-Over-Year Comparison

Compared to the prior year's nine-month period, Fulcrum Therapeutics has experienced a dramatic financial shift. Revenue has plummeted from $80.0 million to $0 due to the absence of collaboration revenue, directly causing a swing from net income to a substantial net loss of $54.5 million. While operating expenses, specifically R&D and G&A, have decreased, this cost reduction is overshadowed by the loss of income. The company's liquidity has also weakened, with both cash and marketable securities declining, while the accumulated deficit has grown, underscoring a more precarious financial position.

Key Financial Figures

• $0.001 — ch registered Common stock, par value $0.001 per share FULC The Nasdaq Global Ma
• $9.7 million — s since our inception. Our net loss was $9.7 million for the year ended December 31, 2024. O
• $54.5 million — ded December 31, 2024. Our net loss was $54.5 million for the nine months ended September 30,
• $573.9 million — 2025, we had an accumulated deficit of $573.9 million. We will need substantial additional

Filing Documents

• fulc-20250930.htm (10-Q) — 2772KB
• fulc-ex31_1.htm (EX-31.1) — 14KB
• fulc-ex31_2.htm (EX-31.2) — 14KB
• fulc-ex32_1.htm (EX-32.1) — 8KB
• fulc-ex32_2.htm (EX-32.2) — 7KB
• 0001193125-25-254633.txt ( ) — 10172KB
• fulc-20250930.xsd (EX-101.SCH) — 1308KB
• fulc-20250930_htm.xml (XML) — 1846KB

Financial Statements

Financial Statements 1 Consolidated Balance Sheets as of September 30, 2025 and December 31, 2024 1 Consolidated Statements of Operations and Comprehensive (Loss) Income for the three and nine months ended September 30, 2025 and 2024 2 Consolidated Statements of Stockholders' Equity for the three and nine months ended September 30, 2025 and 2024 3 Consolidated Statements of Cash Flows for the nine months ended September 30, 2025 and 2024 4

Notes to Consolidated Financial Statements

Notes to Consolidated Financial Statements 5 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 19 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 29 Item 4.

Controls and Procedures

Controls and Procedures 29 PART II. OTHER INFORMATION 30 Item 1.

Legal Proceedings

Legal Proceedings 30 Item 1A.

Risk Factors

Risk Factors 30 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 70 Item 3. Defaults Upon Senior Securities 70 Item 4. Mine Safety Disclosures 70 Item 5. Other Information 70 Item 6. Exhibits 71

Signatures

Signatures 72 In this Quarterly Report on Form 10-Q, unless otherwise stated or as the context otherwise requires, references to "Fulcrum," "Fulcrum Therapeutics," "the Company," "we," "us," "our" and similar references refer to Fulcrum Therapeutics, Inc. together with its consolidated subsidiary. The Fulcrum Therapeutics logo and other trademarks or service marks of Fulcrum Therapeutics, Inc. appearing in this Quarterly Report on Form 10-Q are the property of Fulcrum Therapeutics, Inc. This Quarterly Report on Form 10-Q also contains registered marks, trademarks and trade names of other companies. All other trademarks, registered marks and trade names appearing herein are the property of their respective holders.

—FINANCI AL INFORMATION

PART I—FINANCI AL INFORMATION

Financi al Statements

Item 1. Financi al Statements. Fulcrum Therapeutics, Inc. Consolidated Ba lance Sheets (In thousands, except share and per share amounts) (Unaudited) September 30, 2025 December 31, 2024 Assets Current assets: Cash and cash equivalents $ 47,078 $ 58,212 Marketable securities 153,567 182,809 Unbilled accounts receivable — 2,096 Prepaid expenses and other current assets 5,218 6,806 Total current assets 205,863 249,923 Property and equipment, net 3,171 3,900 Operating lease right-of-use assets 4,614 5,684 Restricted cash 1,201 1,201 Other assets 9 10 Total assets $ 214,858 $ 260,718 Liabilities and stockholders' equity Current liabilities: Accounts payable $ 2,856 $ 1,164 Accrued expenses and other current liabilities 6,428 7,694 Operating lease liability, current 2,348 2,186 Total current liabilities 11,632 11,044 Operating lease liability, excluding current portion 4,663 6,443 Other liabilities, excluding current portion 197 197 Total liabilities 16,492 17,684 Commitments and contingencies (Note 12) Stockholders' equity: Preferred stock, $ 0.001 par value; 5,000,000 shares authorized; no shares issued or outstanding — — Common stock, $ 0.001 par value; 200,000,000 shares authorized; 54,108,438 and 53,968,303 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively 54 54 Additional paid-in capital 772,015 762,248 Accumulated other comprehensive gain 241 130 Accumulated deficit ( 573,944 ) ( 519,398 ) Total stockholders' equity 198,366 243,034 Total liabilities and stockholders' equity $ 214,858 $ 260,718 The accompanying notes are an integral part of these financial statements. 1 Fulcrum Therapeutics, Inc. Consolidated Statements of Oper ations and Comprehensive (Loss) Income (In thousands, except per share data) (Unaudited) Three Month

Notes to Consolidated Financial Statements

Notes to Consolidated Financial Statements 1. Nature of the Business and Basis of Presentation Fulcrum Therapeutics, Inc. (the "Company") was incorporated in Delaware on August 18, 2015. The Company is focused on developing small molecules to improve the lives of patients with genetically-defined rare diseases in areas of high unmet medical need. The Company is subject to a number of risks similar to other companies in the biotechnology industry, including, but not limited to, risks of failure of preclinical studies and clinical trials, dependence on key personnel, protection of proprietary technology, reliance on third party organizations, risks of obtaining regulatory approval for any product candidate that it may develop, development by competitors of technological innovations, compliance with government regulations, and the need to obtain additional financing. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical and clinical testing, and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel infrastructure and extensive compliance-reporting capabilities. Even if the Company's development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales. Basis of Presentation The accompanying consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America ("GAAP"). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification ("ASC") and Accounting Standards Updates ("ASU") of the Financial Accounting Standards Board ("FASB"). The accompanying consolidated financial statements and footnotes to the financial statements have been prepared on the same basis as the most

View Full Filing

View this 10-Q filing on SEC EDGAR